Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects

AIMS: The safety and pharmacokinetics of single and multiple doses of a novel mGlu(2/3) receptor agonist prodrug, MGS0274 besylate (TS‐134), were investigated in healthy subjects. METHODS: Phase 1 single‐ascending dose (5–20 mg) and multiple‐ascending dose titration (5–80 mg) studies were conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Mai, Marcy, Brian, Kinoshita, Kohnosuke, Fukasawa, Misako, Hikichi, Hirohiko, Chaki, Shigeyuki, Okuyama, Shigeru, Gevorkyan, Hakop, Yoshida, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576618/
https://www.ncbi.nlm.nih.gov/pubmed/32353162
http://dx.doi.org/10.1111/bcp.14331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576618/
https://www.ncbi.nlm.nih.gov/pubmed/32353162
http://dx.doi.org/10.1111/bcp.14331

Ejemplares similares